3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
2
Head & Neck
2
Sarcoma
1
NET
1
Lymphoid
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Endocrine
1
Dermatologic
1
CNS
1
Breast
1
Conditions
Sarcoma
2
Pancreatic Neoplasms
2
Ovarian Neoplasms
2
Breast Neoplasms
2
Thyroid Neoplasms
1
Thyroid Cancer, Papillary
1
Thoracic Neoplasms
1
Salivary Gland Neoplasms
1
Respiratory Tract Neoplasms
1
Respiratory Tract Diseases
1
Prostatic Neoplasms
1
Neuroendocrine Tumors
1
Neoplasms by Site
1
Neoplasms
1
Melanoma
1
Lymphoma, Large-Cell, Anaplastic
1
Intestinal Neoplasms
1
Intestinal Diseases
1
Head and Neck Neoplasms
1
Gastrointestinal Neoplasms
1
Gastrointestinal Diseases
1
Digestive System Neoplasms
1
Digestive System Diseases
1
Colorectal Neoplasms
1
Colonic Diseases
1
Cholangiocarcinoma
1
Carcinoma, Renal Cell
1
Carcinoma, Bronchogenic
1
Bronchial Neoplasms
1
Brain Neoplasms
1
Interventions
pembrolizumab
2
belinostat
2
Surveys and Questionnaires
2
Radiosurgery
2
Nivolumab
2
Magnetic Resonance Spectroscopy
2
Cisplatin
2
trastuzumab deruxtecan
1
trametinib
1
tislelizumab
1
tipifarnib
1
temsirolimus
1
spartalizumab
1
selpercatinib
1
romidepsin
1
repotrectinib
1
regorafenib
1
pazopanib
1
larotrectinib
1
durvalumab
1
cemiplimab
1
cc-486
1
alectinib
1
Valproic Acid
1
Transurethral Resection of Prostate
1
Tamoxifen
1
Sunitinib
1
Specimen Handling
1
Sirolimus
1
Radiotherapy
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Thyroid Neoplasms
×
alectinib
×
Sarcoma
×
Clear all
NCT04644315
2023-08-07
ALpha-T
Hoffmann-La Roche
Phase 2
Terminated
1 enrolled
5 charts